The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Open accessAbstract
Background: In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life compared with placebo. In May 2019, tafamidis received expedited approval from the US Food and Drug Administration as a breakthrough drug for a rare disease. However, at $225 000 per year, it is the most expensive cardiovascular drug ever launched in the United States, and its long-term cost-effectiveness and budget impact are uncertain. We therefore aimed to estimate the cost-effectiveness of tafamidis and its potential effect on US health care spending. Methods: We developed a Markov model of patients with wild-type or variant transthyretin amyloid cardiomyopathy and heart failure (mean age, 74.5 years) using inputs from the ATTR-ACT trial (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial), published literature, US Food and Drug Administration review documents, healthcare claims, and national survey data. We compared no disease–specific treatment (“usual care”) with tafamidis therapy. The model reproduced 30-month survival, quality of life, and cardiovascular hospitalization rates observed in ATTR-ACT; future projections used a parametric survival model in the control arm, with constant hazards reduction in the tafamidis arm. We discounted future costs and quality-adjusted life-years by 3% annually and examined key parameter uncertainty using deterministic and probabilistic sensitivity analyses. The main outcomes were lifetime incremental cost-effectiveness ratio and annual budget impact, assessed from the US healthcare sector perspective. This study was independent of the ATTR-ACT trial sponsor. Results: Compared with usual care, tafamidis was projected to add 1.29 (95% uncertainty interval, 0.47–1.75) quality-adjusted life-years at an incremental cost of $1 135 000 (872 000–1 377 000), resulting in an incremental cost-effectiveness ratio of $880 000 (697 000–1 564 000) per quality-adjusted life-year gained. Assuming a threshold of $100 000 per quality-adjusted life-year gained and current drug price, tafamidis was cost-effective in 0% of 10 000 probabilistic simulations. A 92.6% price reduction from $225 000 to $16 563 would be necessary to make tafamidis cost-effective at $100 000/quality-adjusted life-year. Results were sensitive to assumptions related to long-term effectiveness of tafamidis. Treating all eligible patients with transthyretin amyloid cardiomyopathy in the United States with tafamidis (n=120 000) was estimated to increase annual healthcare spending by $32.3 billion. Conclusions: Treatment with tafamidis is projected to produce substantial clinical benefit but would greatly exceed conventional cost-effectiveness thresholds at the current US list price. On the basis of recent US experience with high-cost cardiovascular medications, access to and uptake of this effective therapy may be limited unless there is a large reduction in drug costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857 · cited 3×
“Input Parameters Parameter Base-Case Value Range in Sensitivity Analyses Distribution for Probabilistic Analyses Source(s) Transition probabilities Rate of cardiovascular hospitalizations, per person per year 0.70 0.62–0.80 Log-normal Maurer et al 2018,2 Center for Drug Evaluation and Research 20194 Proportion of card…”
BackgroundMethodInfluentialSelf-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Self-citationApplied Survival Analysis: Regression Modeling of Time‐to‐Event Data
Hosmer, D. W., Lemeshow, S., & May, S. (2008) · Wiley Series in Probability and Statistics · doi:10.1002/9780470258019 · Cited by 1,298
Transthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Self-citationHarris-Kojetin, L. (2016) · PubMed · doi:10.13140/rg.2.1.1207.6407 · Cited by 688
Monitoring clinical changes in patients with heart failure: A comparison of methods
Spertus, J., Peterson, E., Conard, M. W., Heidenreich, P. A., Krumholz, H. M., Jones, P., McCullough, P. A., Pina, I., Tooley, J., Weintraub, W. S., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.010 · Cited by 562
Self-citationAnderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000042 · Cited by 519
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Self-citationWadhera, R. K., Joynt Maddox, K. E., Wasfy, J. H., Haneuse, S., Shen, C., & Yeh, R. W. (2018) · JAMA · doi:10.1001/jama.2018.19232 · Cited by 342
Self-citationGilstrap, L. G., Dominici, F., Wang, Y., El-Sady, M. S., Singh, A., Di Carli, M. F., Falk, R. H., & Dorbala, S. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.118.005407 · Cited by 260
Navar, A. M., Taylor, B., Mulder, H., Fievitz, E., Monda, K. L., Fievitz, A., Maya, J. F., López, J. A. G., & Peterson, E. D. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3451 · Cited by 146
Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
Kazi, D. S., Garber, A. M., Shah, R. U., Dudley, R. A., Mell, M. W., Rhee, C., Moshkevich, S., Boothroyd, D. B., Owens, D. K., & Hlatky, M. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1999 · Cited by 108
Self-citationProfessional fee ratios for US hospital discharge data.
Peterson, C., Xu, L., Florence, C., Grosse, S. D., & Annest, J. L. (2015) · Medical Care · doi:10.1097/mlr.0000000000000410 · Cited by 88
Sandhu, A. T., Ollendorf, D. A., Chapman, R. H., Pearson, S. D., & Heidenreich, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0057 · Cited by 81
Reforming the Orphan Drug Act for the 21st Century
Sarpatwari, A., & Kesselheim, A. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1902943 · Cited by 46
Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
Kazi, D. S., Lu, C. Y., Lin, G. A., DeJong, C., Dudley, R. A., Chen, R., & Tseng, C. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3051 · Cited by 26
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Kittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
Self-citationKittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 640
Self-citation
Metadata
- Authors
- Kazi, D. S., Bellows, B. K., Baron, S. J., Shen, C., Cohen, D. J., Spertus, J. A., Yeh, R. W., Arnold, S. V., Sperry, B. W., Maurer, M. S., & Shah, S. J.
- Venue
- Circulation
- Published
- 2020-04-14
- Volume
- 141
- Issue
- 15
- Pages
- 1214-1224
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3006028248
- Cited by
- 263
- References
- 18
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.